Elhabal, S.F.; Mahfouz, O.M.; Elrefai, M.F.M.; Teaima, M.H.; Abdalla, A.; El-Nabarawi, M.
Sustained Intraocular Pressure Reduction Using Bisoprolol-Loaded PLGA Nanoparticles: A Promising Strategy for Enhanced Ocular Delivery with Reduced GFAP Expression Indicative of Lower Glial Activation. Pharmaceutics 2025, 17, 1418.
https://doi.org/10.3390/pharmaceutics17111418
AMA Style
Elhabal SF, Mahfouz OM, Elrefai MFM, Teaima MH, Abdalla A, El-Nabarawi M.
Sustained Intraocular Pressure Reduction Using Bisoprolol-Loaded PLGA Nanoparticles: A Promising Strategy for Enhanced Ocular Delivery with Reduced GFAP Expression Indicative of Lower Glial Activation. Pharmaceutics. 2025; 17(11):1418.
https://doi.org/10.3390/pharmaceutics17111418
Chicago/Turabian Style
Elhabal, Sammar Fathy, Omnia Mohamed Mahfouz, Mohamed Fathi Mohamed Elrefai, Mahmoud H. Teaima, Ahmed Abdalla, and Mohamed El-Nabarawi.
2025. "Sustained Intraocular Pressure Reduction Using Bisoprolol-Loaded PLGA Nanoparticles: A Promising Strategy for Enhanced Ocular Delivery with Reduced GFAP Expression Indicative of Lower Glial Activation" Pharmaceutics 17, no. 11: 1418.
https://doi.org/10.3390/pharmaceutics17111418
APA Style
Elhabal, S. F., Mahfouz, O. M., Elrefai, M. F. M., Teaima, M. H., Abdalla, A., & El-Nabarawi, M.
(2025). Sustained Intraocular Pressure Reduction Using Bisoprolol-Loaded PLGA Nanoparticles: A Promising Strategy for Enhanced Ocular Delivery with Reduced GFAP Expression Indicative of Lower Glial Activation. Pharmaceutics, 17(11), 1418.
https://doi.org/10.3390/pharmaceutics17111418
